RxDoctor Payments Data

Diedra Troutman

Family · Kingwood, TXNPI 1992389985

Payments from drug & device makers

$1,100in general payments, 2019–2025

Across 37 payments — averaging $29.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$145
  • Inspire Medical Systems, Inc.$140
  • Sumitomo Pharma America, Inc.$134
  • Welch Allyn$114
  • AstraZeneca$100
  • Exeltis, USA Inc.$45
  • plus $421 from 15 others

What the payments were for

  • Food & beverage$98690%
  • Other$11410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,100 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$25,287
Medicare patients
39
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$13,243
Pantoprazole Sodium35$1,235
Albuterol Sulfate HfaAlbuterol Sulfate33$623
Mirtazapine17$562
Sertraline Hcl34$539
Levothyroxine Sodium34$337
Tizanidine Hcl17$313
Atorvastatin Calcium54$263
Gabapentin16$228
Lisinopril31$219
Trazodone Hcl25$196
Furosemide40$182
Duloxetine Hcl11$168
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$164
ClopidogrelClopidogrel Bisulfate17$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$13,24313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →